I started serious Investing Journey in Jan 2000 to create wealth through long-term investing and short-term trading; but as from April 2013 my Journey in Investing has changed to create Retirement Income for Life till 85 years old in 2041 for two persons over market cycles of Bull and Bear.

Since 2017 after retiring from full-time job as employee; I am moving towards Investing Nirvana - Freehold Investment Income for Life investing strategy where 100% of investment income from portfolio investment is cashed out to support household expenses i.e. not a single cent of re-investing!

It is 57% (2017 to Aug 2022) to the Land of Investing Nirvana - Freehold Income for Life!


Click to email CW8888 or Email ID : jacobng1@gmail.com



Welcome to Ministry of Wealth!

This blog is authored by an old multi-bagger blue chips stock picker uncle from HDB heartland!

"The market is not your mother. It consists of tough men and women who look for ways to take money away from you instead of pouring milk into your mouth." - Dr. Alexander Elder

"For the things we have to learn before we can do them, we learn by doing them." - Aristotle

It is here where I share with you how I did it! FREE Education in stock market wisdom.

Think Investing as Tug of War - Read more? Click and scroll down



Important Notice and Attention: If you are looking for such ideas; here is the wrong blog to visit.

Value Investing
Dividend/Income Investing
Technical Analysis and Charting
Stock Tips

Thursday 1 November 2012

Biosensors shares down at 20-mth low

1183199
 
Biosensors is reporting its second quarter results on Nov 7 -PHOTO: SPH

SINGAPORE - Shares of Biosensors International fell as much as 5.5 per cent to a 20-month low, which OCBC Investment Research attributed to ongoing concerns over the impact of mandatory price cuts in stents in countries including India, China and Japan.

By 0436 GMT, Biosensors shares were down 2.8 per cent at S$1.055 with 6.8 million shares traded, 1.5 times its average daily volume over the last five sessions. Its shares have plunged 26 per cent since the start of the year, compared with the 25.4 per cent rise in the FTSE ST Mid Cap Index.

OCBC noted that Terumo Corp, which licenses Biosensors' drug-eluting stent technology for a royalty fee, said sales of one of its Nobori drug-eluting stent in Japan were hurt by an official price cut by the National Health Insurance and rising competition from new product launches.

This would affect Biosensors' licensing revenues in the second quarter ended September, OCBC said. Biosensors is reporting its second quarter results on Nov 7. - REUTERS



No comments:

Post a Comment

Related Posts with Thumbnails